Zobrazeno 1 - 10
of 252
pro vyhledávání: '"A. R. Garber"'
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/fe67564343b84621bcf9ee3c542f54c3
Autor:
Jeffrey R. Garber, Vivek Patkar
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Clinicians seeking guidance for evaluating and managing thyroid nodules currently have several resources. The principal ones are narrative clinical guidelines and clinical risk calculators. This paper will review the strengths and weaknesses of both.
Externí odkaz:
https://doaj.org/article/f24baaa61f0f49feb2b474d46d6eac81
Autor:
Haven R. Garber, Akshara Singareeka Raghavendra, Michael Lehner, Wei Qiao, Angelica M. Gutierrez-Barrera, Debu Tripathy, Banu Arun, Nuhad K. Ibrahim
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Patients with hereditary mutations in BRCA1 or BRCA2 (gBRCA1/2) and breast cancer have distinct tumor biology, and encompass a predilection for brain metastasis (BM). We looked into baseline risk of BMs among gBRCA1/2 patients. Patients with
Externí odkaz:
https://doaj.org/article/f030913dffdd4ede9b5d864d22d62e01
Autor:
Genevieve M. Spagnuolo, MBS, Hien T. Tierney, MD, Leslie S. Eldeiry, MD, Luke P. Keffer, BS, Peter M. Sadow, MD, PhD, Jeffrey R. Garber, MD
Publikováno v:
AACE Clinical Case Reports, Vol 8, Iss 3, Pp 142-144 (2022)
Externí odkaz:
https://doaj.org/article/f3f9273ad59141998e50609199235b7b
Autor:
Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber, Ryan Sun, Senthil Damodaran, Rashmi K. Murthy, David Ramirez, Meghan Karuturi, Rachel M. Layman, Nuhad Ibrahim, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Elizabeth Ravenberg, Alyson Clayborn, Qing Qing Ding, W. Fraser Symmans, Sabitha Prabhakaran, Alastair M. Thompson, Vicente Valero, Debu Tripathy, Lei Huo, Stacy L. Moulder, Jennifer K. Litton
Publikováno v:
Breast Cancer Research and Treatment. 199:457-469
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eeeac865ad0232a7bf89c1bfdbc1ac3c
https://doi.org/10.1007/s10549-023-06929-9
https://doi.org/10.1007/s10549-023-06929-9
Autor:
Alexandre Reuben, Christine N. Spencer, Peter A. Prieto, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, John P. Miller, Xizeng Mao, Mariana Petaccia De Macedo, Jiong Chen, Xingzhi Song, Hong Jiang, Pei-Ling Chen, Hannah C. Beird, Haven R. Garber, Whijae Roh, Khalida Wani, Eveline Chen, Cara Haymaker, Marie-Andrée Forget, Latasha D. Little, Curtis Gumbs, Rebecca L. Thornton, Courtney W. Hudgens, Wei-Shen Chen, Jacob Austin-Breneman, Robert Szczepaniak Sloane, Luigi Nezi, Alexandria P. Cogdill, Chantale Bernatchez, Jason Roszik, Patrick Hwu, Scott E. Woodman, Lynda Chin, Hussein Tawbi, Michael A. Davies, Jeffrey E. Gershenwald, Rodabe N. Amaria, Isabella C. Glitza, Adi Diab, Sapna P. Patel, Jianhua Hu, Jeffrey E. Lee, Elizabeth A. Grimm, Michael T. Tetzlaff, Alexander J. Lazar, Ignacio I. Wistuba, Karen Clise-Dwyer, Brett W. Carter, Jianhua Zhang, P. Andrew Futreal, Padmanee Sharma, James P. Allison, Zachary A. Cooper, Jennifer A. Wargo
Publikováno v:
npj Genomic Medicine, Vol 2, Iss 1, Pp 1-11 (2017)
Melanoma: Tumor differences within a patient may explain heterogeneous responses Patients with metastatic melanoma display molecular and immune differences across tumor sites associated with differential drug responses. A team led by Jennifer Wargo f
Externí odkaz:
https://doaj.org/article/95f4f8da81aa4220b7ea3fea4b7af4b6
Autor:
Jeffrey J. Molldrem, Samir Hanash, Gheath Alatrash, Chantale Bernatchez, Stephen G. Swisher, John V. Heymach, Don L. Gibbons, Jason Roszik, Karen Clise-Dwyer, Kathryn Ruisaard, Mourad Majidi, Boris Sepesi, Jack A. Roth, Ismail M. Meraz, Lorenzo Federico, Lisa S. St. John, Haven R. Garber, Hiroyuki Katayama, Celine Kerros, Satyendra C. Tripathi, Haley L. Peters
Immunotherapies targeting immune checkpoints have proven efficacious in reducing the burden of lung cancer in patients; however, the antigenic targets of these reinvigorated T cells remain poorly defined. Lung cancer tumors contain tumor-associated m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f49907a10f07f5f09abe1a4ce9f79bc7
https://doi.org/10.1158/2326-6066.c.6548756.v1
https://doi.org/10.1158/2326-6066.c.6548756.v1
Autor:
Jeffrey J. Molldrem, Samir Hanash, Gheath Alatrash, Chantale Bernatchez, Stephen G. Swisher, John V. Heymach, Don L. Gibbons, Jason Roszik, Karen Clise-Dwyer, Kathryn Ruisaard, Mourad Majidi, Boris Sepesi, Jack A. Roth, Ismail M. Meraz, Lorenzo Federico, Lisa S. St. John, Haven R. Garber, Hiroyuki Katayama, Celine Kerros, Satyendra C. Tripathi, Haley L. Peters
Figure Legends for Supplementary Figures S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee9147779faa94ee49c5a8f0c8aefa2
https://doi.org/10.1158/2326-6066.22538363.v1
https://doi.org/10.1158/2326-6066.22538363.v1
Autor:
Jeffrey J. Molldrem, Samir Hanash, Gheath Alatrash, Chantale Bernatchez, Stephen G. Swisher, John V. Heymach, Don L. Gibbons, Jason Roszik, Karen Clise-Dwyer, Kathryn Ruisaard, Mourad Majidi, Boris Sepesi, Jack A. Roth, Ismail M. Meraz, Lorenzo Federico, Lisa S. St. John, Haven R. Garber, Hiroyuki Katayama, Celine Kerros, Satyendra C. Tripathi, Haley L. Peters
Supplementary Figure S1. Lung cancer cell lines do not express NE and P3 gene transcripts. Supplementary Figure S2. CTL proliferate in the presence of NE-exposed lung cancer cells. Supplementary Figure S3. HLA class I presentation of mutant neoantige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f2c731ad70e3270e82cab95deaa7b6d
https://doi.org/10.1158/2326-6066.22538360
https://doi.org/10.1158/2326-6066.22538360
Autor:
Haven R. Garber, Sreyashi Basu, Sonali Jindal, Akshara Singareeka Raghavendra, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, James P. Allison, Jennifer Litton
Publikováno v:
Cancer Research. 82:P2-14
Background: The checkpoint inhibitors atezolizumab (anti-PD-L1) and pembrolizumab (anti-PD-1) are FDA approved for the treatment of patients with PD-L1 positive, metastatic triple negative breast cancer in combination with chemotherapy. The response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de66082e431b2d0ae6046c134e25ffa0
https://doi.org/10.1158/1538-7445.sabcs21-p2-14-14
https://doi.org/10.1158/1538-7445.sabcs21-p2-14-14